Endoscope Repair MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy Service TypeBy Service ProviderBy Contract Type

Endoscope repair services cover the inspection, diagnosis and restoration of reusable flexible and rigid endoscopes used in gastrointestinal, pulmonary, urological, gynecological and orthopedic procedures, addressing damage to the insertion tube, optical and lens assembly, video imaging chain, light-guide cables and control handles. Buyers are hospitals, ambulatory surgical centers and dedicated endoscopy clinics that maintain in-service scope fleets, sourcing repair either from the original device manufacturer, independent third-party repair providers or in-house biomedical engineering teams. Services range from single-incident repairs to scheduled preventive maintenance and annual service contracts intended to extend scope service life and reduce unplanned downtime.

Growth of 7.97% a year carries the global endoscope repair market from USD 2.3 billion in 2025 to USD 4.58 billion in 2034. The full series behind that rate covers USD 1.55 billion in 2020, USD 2.13 billion in 2024, USD 2.48 billion in 2026 and USD 3.37 billion in 2030, with 2025 as the base year.

27% of 2025 revenue sits in Colonoscope, worth USD 0.62 billion and rising to USD 1.19 billion at 26% by 2034, the largest type line in both years. Growth is fastest in Bronchoscope at 10.09% and slowest in Arthroscope at 6.38%. The lines gaining share are Bronchoscope, Hysteroscope and Esophagoscope. Colonoscope, Gastroscope, Laparoscope and Arthroscope lose share without losing revenue.

By application, Hospitals accounts for 62.2% of 2025 revenue at USD 1.43 billion, reaching USD 2.56 billion and 55.9% by 2034. ASCs grows faster at 11.13% against 7.55%, moving from 23.9% of revenue to 27.9% by 2034. This axis divides the same revenue as the type split instead of adding to it, so the two are read together and never summed.

North America is the largest region at 37.8% of 2025 revenue, worth USD 0.87 billion and reaching USD 1.6 billion by 2034. Europe follows at 27%, moving from USD 0.62 billion to USD 1.15 billion, and Middle East and Africa is the smallest at 5.2%. Because Asia Pacific take share, the revenue added by 2034 concentrates instead of spreading across all five regions.

The 2025 total is arrived at by triangulating published aggregates against category proxies, not by an independent count. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, seven type lines and five segmentation axes across a fifteen-year window.

• Revenue grows from USD 2.3 billion in 2025 to USD 4.58 billion in 2034, a compound annual rate of 7.97%, having reached USD 2.13 billion in 2024 from USD 1.55 billion in 2020.
• The largest line by type is Colonoscope, worth USD 0.62 billion and 27% of revenue in 2025, rising to USD 1.19 billion and 26% by 2034.
• Fastest growth on the type axis belongs to Bronchoscope: 10.09% a year, USD 0.35 billion to USD 0.82 billion, and a share moving from 15.2% to 17.9%.
• Against a base case of USD 4.58 billion in 2034, the study also reports a bear case at USD 4.08 billion and a bull case at USD 5.07 billion, with the assumptions behind each set out separately.
• North America holds 37.8% of global revenue in 2025 at USD 0.87 billion, the largest of the five regions tracked, and reaches USD 1.6 billion by 2034.
• 88.5% of North America's base-year revenue comes from the United States alone: USD 0.77 billion in 2025, rising to USD 1.39 billion by 2034, which is why it is that region's worked example.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.

Three movements define the forecast period in the global endoscope repair market: how the type mix changes, where regional weight shifts, and the rate at which the total compounds.

None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; the movement is in which of them captures the revenue added.

The type mix tilts toward Bronchoscope. 10.09% against 6.38%: that gap, between Bronchoscope and Arthroscope, is the largest on the type axis. Bronchoscope takes its share of revenue from 15.2% to 17.9% while Arthroscope gives up ground, from 10% to 9%. Neither contracts: USD 0.35 billion becomes USD 0.82 billion, USD 0.23 billion becomes USD 0.41 billion. What the spread decides is which of them a supplier's revenue is exposed to.

Asia Pacific gain regional share. Asia Pacific moves from 23.9% of revenue in 2025 to 29% in 2034, worth USD 0.55 billion rising to USD 1.33 billion. Share moves off the others in turn: North America at 37.8% moving to 34.9%, Europe at 27% moving to 25.1%, Latin America at 6.1% moving to 5.9%, Middle East and Africa at 5.2% moving to 5%, each still growing in revenue terms. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.

Fifteen years without a discontinuity. Year by year the total runs USD 1.55 billion in 2020, USD 2.13 billion in 2024, USD 2.3 billion in 2025, USD 2.48 billion in 2026, USD 3.37 billion in 2030 and USD 4.58 billion in 2034. No year breaks the trajectory, and the 7.97% forecast rate compares with 8.22% recorded over 2020-2025, a continuation, not an inflection. That moves the planning question away from timing a turn and onto the type and regional mixes, where the actual movement is.

Bronchoscope carries the market's growth rate

Growth in the global endoscope repair market comes from three measurable sources over 2026-2034: the market's own compounding at 7.97%, the share gained by faster-growing type lines, and expansion in the regions taking a larger part of global revenue.

What holds the forecast back

Upside case: USD 5.07 billion by 2034

The total depends on a single line

In North America, 37.8% of global revenue puts 2025 at USD 0.87 billion rising to USD 1.6 billion in 2034. Among the five regions it ranks first by revenue in both years.

Its share moves to 34.9% by 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Segment composition follows the global pattern: Colonoscope largest at 27% of 2025 revenue, Bronchoscope fastest at 10.09%. Per-axis and per-country detail for North America sits in the full report.

USD 0.77 billion of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 1.39 billion by 2034. Because it is 88.5% of the region in the base year, North America's totals move with this one country instead of a spread of them. Against regional totals of USD 0.87 billion in 2025 and USD 1.6 billion in 2034, it is the country the full report breaks out in detail.

the United States buys along the same lines as the market globally; Colonoscope first at 27% of 2025 revenue and 26% in 2034, Bronchoscope fastest at 10.09% on a share moving from 15.2% to 17.9%. Its 88.5% weight in North America means those movements carry straight into the regional totals. The United States carries its own type breakdown in the full report.

FDA regulates medical devices under the Federal Food, Drug, and Cosmetic Act; servicing and repair of endoscopes is distinguished from remanufacturing, with the FDA drawing that line based on whether the work restores the device to original specifications or alters its intended performance. Servicers must comply with Quality System Regulation obligations that apply to their activity, and repaired devices must continue to meet the original premarket clearance basis without introducing new risks. Facilities performing repair are expected to maintain complete service records, use compatible replacement parts, and label serviced units appropriately, avoiding any claim that unfairly implies the device is new or covered by a different clearance than the original manufacturer's.

In the United States the field is Stryker, Medivators, Olympus, Hoya Corporation, Smith & Nephew, Fujifilm Holdings, Karl Storz, Medserv, Endoscopy Repair Specialis, Fibertech, Associated Endoscopy, EndocorpUSA, Medical Optics and HMB En. The commercially relevant division is 27% of 2025 revenue in Colonoscope, where the volume is, against 10.09% growth in Bronchoscope, where share moves. Per-company positioning and share at country level are in the full report only.

4.3% of global revenue is generated in Canada; USD 0.1 billion in 2025, reaching USD 0.21 billion in 2034, and 11.5% of North America.

Europe holds 27% of the global endoscope repair market in 2025, worth USD 0.62 billion and reaches USD 1.15 billion by 2034. Among the five regions it ranks second by revenue in both years.

25.1% of global revenue sits here in 2034, below the 2025 level, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Within the region the type split tracks the global one; 27% of 2025 revenue in Colonoscope, fastest growth of 10.09% in Bronchoscope. Europe is reported axis by axis and country by country in the full study.

Germany is the largest market within Europe, generating USD 0.19 billion in 2025 and projected to reach USD 0.33 billion by 2034. At 30.6% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. Set against USD 0.62 billion and USD 1.15 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Germany buys along the same lines as the market globally; Colonoscope first at 27% of 2025 revenue and 26% in 2034, Bronchoscope fastest at 10.09% on a share moving from 15.2% to 17.9%. With 30.6% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports Germany by type separately.

German medical device servicing sits within the EU Medical Device Regulation framework as implemented nationally through the Medizinprodukterecht-Durchführungsgesetz, with oversight from the national competent authority alongside notified bodies. Repair providers must distinguish routine servicing from remanufacturing, since remanufacturing triggers the full obligations of a manufacturer, including conformity assessment and CE marking under a new identity. Servicers are expected to work to recognized quality management standards for medical devices, keep traceable repair documentation, and ensure sterilization and functional testing restore the endoscope to its validated original specification before return to clinical use.

The suppliers tracked in this study (Stryker, Medivators, Olympus, Hoya Corporation, Smith & Nephew, Fujifilm Holdings, Karl Storz, Medserv, Endoscopy Repair Specialis, Fibertech, Associated Endoscopy, EndocorpUSA, Medical Optics and HMB En) compete in Germany across the type lines above. The commercially relevant division is 27% of 2025 revenue in Colonoscope, where the volume is, against 10.09% growth in Bronchoscope, where share moves. That makes Europe a 27% share of 2025 global revenue, USD 0.62 billion rising to USD 1.15 billion, for any supplier deciding where to concentrate.

6.5% of global revenue is generated in the United Kingdom; USD 0.15 billion in 2025, reaching USD 0.26 billion in 2034, and 24.2% of Europe.

France is sized at USD 0.11 billion in 2025, rising to USD 0.2 billion by 2034; 4.8% of global revenue and 17.7% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

Asia Pacific holds 23.9% of the global endoscope repair market in 2025, worth USD 0.55 billion and reaches USD 1.33 billion by 2034. It is a leading region on this axis, third by revenue throughout the period.

29% of global revenue sits here by 2034, up from the 2025 level, because it outgrows the market's 7.97%; the revenue added here is disproportionate to where the region started.

Colonoscope leads here as it does globally, at 27% of 2025 revenue, and Bronchoscope again grows fastest at 10.09%. Asia Pacific is reported axis by axis and country by country in the full study.

USD 0.19 billion of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 0.44 billion by 2034. At 34.5% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. Regional revenue of USD 0.55 billion in 2025 and USD 1.33 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

The type pattern in China is the global one: 27% of 2025 revenue in Colonoscope, 26% by 2034, against 10.09% growth in Bronchoscope taking it from 15.2% to 17.9%. Because the country carries 34.5% of Asia Pacific, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. China carries its own type breakdown in the full report.

China's National Medical Products Administration governs medical devices, and endoscope repair and maintenance services fall under provisions for medical device business operation and quality management rather than under a separate specific repair statute. Entities performing repair must generally hold appropriate business licensing, follow the manufacturer's technical documentation where available, and ensure that reprocessed or serviced devices continue to meet the registration certificate under which the original device was approved. Hospitals and third-party service providers are expected to maintain maintenance records and comply with quality management expectations that mirror those applied to medical device operation more broadly, without claiming equivalence to a newly registered device.

Competition in China runs between the suppliers this study tracks: Stryker, Medivators, Olympus, Hoya Corporation, Smith & Nephew, Fujifilm Holdings, Karl Storz, Medserv, Endoscopy Repair Specialis, Fibertech, Associated Endoscopy, EndocorpUSA, Medical Optics and HMB En. Two different problems sit on the same axis: holding Colonoscope at 27% of 2025 revenue, and taking Bronchoscope while it grows at 10.09%. Weighting toward Asia Pacific means competing for 23.9% of 2025 global revenue, a base of USD 0.55 billion moving to USD 1.33 billion across the forecast period.

Japan is sized at USD 0.14 billion in 2025, rising to USD 0.32 billion by 2034; 6.1% of global revenue and 25.5% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

India is sized at USD 0.09 billion in 2025, rising to USD 0.25 billion by 2034; 3.9% of global revenue and 16.4% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

6.1% of the global endoscope repair market sits in Latin America in 2025, worth USD 0.14 billion rising to USD 0.27 billion in 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.

Share settles at 5.9% in 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Colonoscope leads here as it does globally, at 27% of 2025 revenue, and Bronchoscope again grows fastest at 10.09%. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.

Brazil is the largest market within Latin America, generating USD 0.08 billion in 2025 and projected to reach USD 0.15 billion by 2034. At 57.1% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. The region itself runs USD 0.14 billion to USD 0.27 billion over the same period, and this is the market carrying the country-level detail in the full report.

Brazil buys along the same lines as the market globally; Colonoscope first at 27% of 2025 revenue and 26% in 2034, Bronchoscope fastest at 10.09% on a share moving from 15.2% to 17.9%. With 57.1% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Brazil carries its own type breakdown in the full report.

ANVISA, Brazil's national health surveillance agency, regulates medical devices including the servicing of endoscopes through its broader health product oversight framework. Technical assistance providers must operate under a sanitary license and are expected to follow good practice guidance covering cleaning, disinfection, and functional testing before a repaired unit returns to use. ANVISA distinguishes routine maintenance from modification that would require fresh regulatory approval, so a servicer altering the device's original design or intended function would trigger obligations closer to those of a manufacturer. Documentation of each service intervention is expected to be retained and available for inspection.

Competition in Brazil runs between the suppliers this study tracks: Stryker, Medivators, Olympus, Hoya Corporation, Smith & Nephew, Fujifilm Holdings, Karl Storz, Medserv, Endoscopy Repair Specialis, Fibertech, Associated Endoscopy, EndocorpUSA, Medical Optics and HMB En. Colonoscope, at 27% of 2025 revenue, is where the volume sits, and Bronchoscope, growing at 10.09%, is where position changes hands over the forecast period. Weighting toward Latin America means competing for 6.1% of 2025 global revenue, a base of USD 0.14 billion moving to USD 0.27 billion across the forecast period.

1.7% of global revenue is generated in Mexico; USD 0.04 billion in 2025, reaching USD 0.09 billion in 2034, and 28.6% of Latin America.

USD 0.12 billion of 2025 revenue is generated in Middle East and Africa, 5.2% of the global endoscope repair market with USD 0.23 billion projected for 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

Its share moves to 5% by 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

The type mix reported at global level applies here, with Colonoscope the largest line at 27% of 2025 revenue and Bronchoscope the fastest-growing at 10.09%. Middle East and Africa is reported axis by axis and country by country in the full study.

USD 0.05 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 0.09 billion by 2034. At 41.7% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Against regional totals of USD 0.12 billion in 2025 and USD 0.23 billion in 2034, it is the country the full report breaks out in detail.

The type pattern in Saudi Arabia is the global one: 27% of 2025 revenue in Colonoscope, 26% by 2034, against 10.09% growth in Bronchoscope taking it from 15.2% to 17.9%. Since 41.7% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-type revenue for Saudi Arabia appears on its own in the full report.

The Saudi Food and Drug Authority oversees medical devices in the Kingdom, and endoscope repair activity is addressed through its medical device establishment licensing framework rather than a standalone repair regulation. Providers offering maintenance or repair services are generally expected to register as an authorized medical device establishment, follow the authority's quality requirements for device handling, and ensure any replacement components or reprocessing steps do not compromise the device's original approval basis. Given reliance on imported endoscopy equipment, repair providers are also expected to coordinate with the original manufacturer's technical guidance where conformity to recognized standards is required for continued clinical use.

Competition in Saudi Arabia runs between the suppliers this study tracks: Stryker, Medivators, Olympus, Hoya Corporation, Smith & Nephew, Fujifilm Holdings, Karl Storz, Medserv, Endoscopy Repair Specialis, Fibertech, Associated Endoscopy, EndocorpUSA, Medical Optics and HMB En. Two different problems sit on the same axis: holding Colonoscope at 27% of 2025 revenue, and taking Bronchoscope while it grows at 10.09%. That makes Middle East and Africa a 5.2% share of 2025 global revenue, USD 0.12 billion rising to USD 0.23 billion, for any supplier deciding where to concentrate.

Within Middle East and Africa, South Africa accounts for 25% of regional revenue and 1.3% of the global total, worth USD 0.03 billion in 2025 and USD 0.06 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Application, Service Type, Service Provider, Contract Type, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.